Sarepta Therapeutics (SRPT) Retained Earnings (2010 - 2026)
Sarepta Therapeutics (SRPT) posted quarterly Retained Earnings of -$121000.0 for Q1 2026, down 455.88% year-over-year from $34000.0 in Q1 2025, and up 100.0% quarter-over-quarter from -$4.9 billion in Q4 2025.
Sarepta Therapeutics (SRPT) Retained Earnings (2010 - 2026) Analysis & Trends
Sarepta Therapeutics' Retained Earnings history runs 17 years deep, the most recent figure standing at -$121000.0 for Q1 2026.
- In Q1 2026, Retained Earnings fell 455.88% year-over-year to -$121000.0; the TTM figure through Mar 2026 stood at -$121000.0 (down 455.88% YoY), while the FY2025 annual figure was -$4.9 billion, down 15.82% from the prior year.
- Retained Earnings for Q1 2026 stood at -$121000.0, up from -$4.9 billion in the prior quarter.
- The five-year high for Retained Earnings was $918000.0 in Q4 2023, with the low at -$4.9 billion in Q4 2025.
- The 5-year median for Retained Earnings is -$2.5 million (2022), against an average of -$1.8 billion.
- The sharpest annual moves came in 2023 and 2025: Retained Earnings tumbled 1446629.08% in 2023, then soared 104.92% in 2025.
- Sarepta Therapeutics' Retained Earnings stood at -$3.9 billion in 2022, then surged by 100.02% to $918000.0 in 2023, then tumbled by 458811.76% to -$4.2 billion in 2024, then dropped by 15.82% to -$4.9 billion in 2025, then surged by 100.0% to -$121000.0 in 2026.
- Business Quant data shows SRPT's Retained Earnings at -$121000.0 in Q1 2026, -$4.9 billion in Q4 2025, and $220000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Sarepta Therapeutics | 1.91 Bn | 1.12 Bn | 251.87 Mn | -4.55 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.55 Bn |
| Mar 31, 2026 | -121,000.00 |
| Dec 31, 2025 | -4.88 Bn |
| Sep 30, 2025 | 220,000.00 |
| Jun 30, 2025 | -51,000.00 |
| Mar 31, 2025 | 34,000.00 |
| Dec 31, 2024 | -4.21 Bn |
| Sep 30, 2024 | -4.37 Bn |
| Jun 30, 2024 | -4.40 Bn |
| Mar 31, 2024 | -691,000.00 |
| Dec 31, 2023 | 918,000.00 |
| Sep 30, 2023 | -4.49 Bn |
| Jun 30, 2023 | -1.06 Mn |
| Mar 31, 2023 | -4.43 Bn |
| Dec 31, 2022 | -3.91 Bn |
| Sep 30, 2022 | -3.21 Mn |
| Jun 30, 2022 | -2.49 Mn |
| Mar 31, 2022 | -306,000.00 |
| Dec 31, 2021 | -3.21 Bn |
| Sep 30, 2021 | -3.08 Bn |